Bryxta 100 Mg Inj

bryxta 100mg Injection is an anticancer medicine consisting of the active ingredient Bevacizumab. This medicine is developed to prevent the growth of tumors. It is indicated along with other chemotherapy drugs to treat metastatic breast cancer, brain cancer, cervical cancer, kidney cancer, lung cancer, and colorectal cancer. It is also used to treat cancers of the ovary, fallopian tube or primary peritoneal cancer. Use effective birth control during the treatment and for at least six months after the last dose. bryxta 100mg Injection is not recommended for adolescents and children under the age of 18

Uses of bryxta 100mg Injection

Your physician or nurse will administer bryxta 100mg Injection as an intravenous infusion. The infusion should be given immediately after the dilution.

Bevacizumab is a recombinant humanized monoclonal antibody that works as a targeted therapy in the treatment of various advanced cancers. It produces its action by selectively binding to the protein called vascular endothelial growth factor A (VEGF-A), which is present in the lining of blood and lymph vessels in the body. It interrupts the interaction of VEGF-A with its receptors. This further inhibits the formation of blood vessels that supply oxygen and nutrients to the tumor. As a result, it slows down the rate of progression of cancer.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

cold chain

11